Keyphrases
1-to-1
16%
Abdominal Adiposity
16%
Abdominal Fat
16%
Adipose Tissue
16%
Adiposity
100%
African American
16%
Aggression
16%
Antipsychotic Use
16%
Antipsychotic-naïve
16%
Antipsychotics
100%
Aripiprazole
83%
Behavioral Improvement
16%
Body Composition
16%
Cardiometabolic Disease
16%
Clinically Significant
16%
Criterion Standards
16%
Disappearance Rate
16%
Disruptive Behavioral Disorders
33%
Dual-energy X-ray Absorptiometry
33%
First Exposure
16%
Hepatic Tissue
16%
Hyperinsulinemic-euglycemic Clamp
16%
Insulin
16%
Insulin Sensitivity
100%
Intention-to-treat
16%
Isotopically Labeled
16%
Magnetic Resonance Imaging
33%
Metabolic Effects
100%
Metropolitan Areas
16%
Missouri
16%
No Significant Difference
16%
Non-psychotic Disorders
16%
Olanzapine
100%
Overweight or Obesity
16%
Pooled Study
16%
Psychiatric Disorders
16%
Randomized Clinical Trial
100%
Risk-benefit
16%
Risperdone
16%
Risperidone
66%
Sampling Effect
16%
St. Louis
16%
Subcutaneous Fat
16%
Time Effect
16%
Total Body Fat
33%
Treatment Interaction
33%
Medicine and Dentistry
Abdominal Fat
16%
Abdominal Obesity
16%
Absorptiometry
33%
Adipose Tissue
16%
Antipsychotic
83%
Aripiprazole
83%
Body Composition Assessment
16%
Body Fat
33%
Insulin Sensitivity
100%
Intention-to-Treat Analysis
16%
Magnetic Resonance Imaging
33%
Mental Disorder
16%
Olanzapine
100%
Prematurity
16%
Radioactive Tracer
33%
Randomized Clinical Trial
100%
Risperidone
66%
Subcutaneous Fat
16%
Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Obesity
16%
Antipsychotic
83%
Aripiprazole
83%
Behavior Disorder
33%
Olanzapine
100%
Prematurity
16%
Randomized Clinical Trial
100%
Risperidone
66%
Tracer
33%
Neuroscience
Adipose Tissue
16%
Antipsychotic
83%
Aripiprazole
83%
Behavior Disorder
33%
Magnetic Resonance Imaging
33%
Mental Disorder
16%
Olanzapine
100%
Risperidone
66%